The next-generation heart pump to change patients’ lives and create a new standard of care

Descripción del proyecto

Una bomba implantable inteligente para la insuficiencia cardíaca avanzada

La insuficiencia cardíaca es un trastorno potencialmente mortal en el que el corazón es incapaz de bombear suficiente sangre para satisfacer las necesidades del cuerpo. Para los enfermos con una insuficiencia cardíaca avanzada y que son demasiado mayores o no adecuados para un trasplante cardíaco, los dispositivos de asistencia ventricular izquierda (DAVI, o LVAD por sus siglas en inglés) implantables han surgido como una nueva opción de tratamiento. El proyecto financiado con fondos europeos Calypso comercializará un DAVI revolucionario desarrollado por la empresa francesa CORWAVE. Este dispositivo nuevo está basado en una tecnología de vanguardia patentada: la membrana de onda. A diferencia de los dispositivos actuales, que son bombas rotatorias de flujo continuo, CorWave LVAD es una bomba inteligente que produce un flujo sanguíneo fisiológico y pulsátil para devolver una vida normal a los enfermos con unos efectos secundarios mínimos.

Objetivo

Advanced heart failure (HF) is a deadly disease, with a booming incidence driven by durable socio-demographic trends. Left ventricular assist devices (LVADs) are a life-saving therapy for advanced HF patients and represent a billion-euro market. However, only 13% of the 60,000 eligible patients are implanted with current LVADs each year, due to the extremely high rate of severe adverse events (stroke, bleeding, infection) and the limited quality of life.
CorWave is an innovative French SME created in 2011 with a mission to create a new standard of care for advanced HF patients. The company is developing a game-changing LVAD, which relies on a unique and patented breakthrough technology, the wave membrane. Unlike all current devices, which are continuous-flow rotary pumps, CorWave LVAD is a smart pump producing a physiologic and pulsatile blood flow, to restore a normal life to patients with minimal side effects. CorWave LVAD will cut in half severe complications and rehospitalisation costs. CorWave projects to take over 60% of the market and reach up to €1.1 billion of turnover in 2030, by taking advantage of the LVAD market structure, which is very favourable to new entrants (concentrated on a few centres), and by increasing the penetration rate.
We have built a team of 50 experienced people, including world-class experts, and have gained a strong market traction. The clinical centres who support us through letters of intent are worth >25% of the European market. We partner with a network of industrial suppliers and have our own pilot production unit to manufacture prototypes that have proved successful in preclinical studies.
Thanks to EIC Accelerator, CorWave will transform a very promising preclinical prototype (TRL 6-7) into an industrial CE-marked medical device (TRL 8-9) that patients, clinicians and payers are waiting for. EIC Accelerator would place CorWave on a trajectory to become a global medtech leader with an outstanding socioeconomic impact on the EU.

Ámbito científico

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-EIC-SMEInst-2018-2020-3

Régimen de financiación

SME - SME instrument

Coordinador

CORWAVE

Aportación neta de la UEn

€ 2 495 675,00

Dirección

19-23 ALLEE DE L'EUROPE
92110 CLICHY
Francia

Pyme

Sí

Región

Ile-de-France Ile-de-France Hauts-de-Seine

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 3 565 250,00